Studied in RCC patients after 2+ systemic therapies
Studied in RCC patients after 2 or more systemic therapies
The first and only prospective, Phase 3 study of a VEGFR TKI in rrRCC after 2 or more systemic therapies including IO1,2
Study design: Open-label, multicenter study (N=350) in North America and the European Union
Primary endpoint: PFS assessed by a blinded independent radiology review committee
Secondary endpoint: ORR (CR+PR), DOR, OS, tolerability and safety
*Other systemic agents were mTOR inhibitors and cytokines (interferon and interleukin).2
Get an overview of the TIVO-3 study design and its uniqueness within the RCC treatment paradigm from Dr. Pedro C Barata, Director, GU Medical Oncology Research Program at University Hospitals Seidman Cancer Center.
View a video of Dr. Barata covering the importance of the first and only Ph3 data after 2 or more prior regimens that reflects how providers manage RCC patients in the real-world.
Get an overview of the TIVO-3 study design and its uniqueness within the RCC treatment paradigm from Dr. Pedro C Barata, Director, GU Medical Oncology Research Program at University Hospitals Seidman Cancer Center.
View a video of Dr. Barata covering the importance of the first and only Ph3 data after 2 or more prior regimens that reflects how providers manage RCC patients in the real-world.
See results from the pivotal trial.
Explore safety and tolerability.
Reach out to an AVEO Oncology Account Manager.
BID=twice daily; CPI=checkpoint inhibitor; CR=complete response; DOR=duration of response; IMDC=International Metastatic RCC Database Consortium; mTOR=mechanistic target of rapamycin; ORR=overall response rate; OS=overall survival; PR=partial response; PFS=progression-free survival; QD=once daily: RCC=renal cell carcinoma; rrRCC=relapsed/refractory renal cell carcinoma; TKI=tyrosine kinase inhibitor; VEGFR=vascular endothelial growth factor receptor.
References: 1. FOTIVDA (tivozanib) (package insert], Boston, MA: AVEO Pharmaceuticals, Inc, August 2024. 2. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95-104.